1. Home
  2. FGI vs SILO Comparison

FGI vs SILO Comparison

Compare FGI & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

HOLD

Current Price

$6.40

Market Cap

14.0M

Sector

Industrials

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.43

Market Cap

8.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGI
SILO
Founded
1987
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Apparel
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
14.0M
8.0M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
FGI
SILO
Price
$6.40
$0.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
59.3K
132.6K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$135,654,095.00
$72,102.00
Revenue This Year
$3.80
$1.86
Revenue Next Year
$6.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.66
N/A
52 Week Low
$2.28
$0.36
52 Week High
$12.62
$3.37

Technical Indicators

Market Signals
Indicator
FGI
SILO
Relative Strength Index (RSI) 48.81 42.14
Support Level $7.17 $0.42
Resistance Level $9.00 $0.46
Average True Range (ATR) 1.32 0.03
MACD 0.10 0.01
Stochastic Oscillator 22.21 50.52

Price Performance

Historical Comparison
FGI
SILO

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

Share on Social Networks: